KCNT1-Related Epilepsy
Conditions
Brief summary
This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.
Detailed description
This is a Phase 1a, first-in-human, placebo-controlled study consisting of 3 parts. Part 1 is a single ascending dose (SAD) study in up to 40 participants consisting of a screening period of up to 28 days prior to a single dose of ABS-1230 or placebo, with follow-up 7 days and 14 days after dosing. Part 2 is a multiple ascending dose (MAD) study in up to 30 participants consisting of a screening period of up to 28 days, followed by ABS-1230 or placebo once daily for 14 days, with follow-up 7 days and 14 days after dosing is completed. Part 3 is a food effect (FE) study in 12 participants consisting of two doses of ABS-1230 under fasted and fed conditions and in combination with omeprazole with follow-up 7 days and 14 days after dosing is completed. Part 4 is a drug-drug interaction (DDI) study in 10 participants consisting of doses of ABS-1230 in combination with voriconazole, with follow-up 15 days after dosing is completed.
Interventions
Sponsors
Actio Biosciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18 to 55 years, inclusive * Body mass index greater than or equal to 18 to less than or equal to 32 kg/m2 * Medically healthy with no clinically significant medical history, physical examination, vital sign, standard 12-lead ECG, chemistry, hematology, urinalysis, or coagulation results at Screening as deemed by the Investigator * Male and female subjects must use adequate birth control and agree not to donate sperm or eggs for the time periods specified in the protocol
Exclusion criteria
* Positive result for HIV, HBV, or HCV * History of malignancy other than treated basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix * History of alcoholism or recreational drug use within 2 years or a positive alcohol or tobacco test result at screening or first check-in visit * For female participants, must not be pregnant, breastfeeding, or seeking to become pregnant while in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability (incidence, severity, and dose-relationship of adverse events) | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To assess safety and tolerability of ABS-1230 following single and multiple oral administration by determining the incidence, severity, and dose-relationship of adverse events |
| Safety and tolerability (incidence, severity, and dose-relationship of clinically significant changes in laboratory parameters) | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To assess safety and tolerability of ABS-1230 following single and multiple oral administration by determining the incidence, severity, and dose-relationship of clinically significant laboratory changes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Plasma Concentration [Cmax] After Single Dose of ABS-1230 | Measured from Day 1 to End of Study or Early Termination (up to 2 weeks) | To evaluate the pharmacokinetics of single dose of ABS-1230 |
| Maximum Plasma Concentration [AUCinf] After Single Dose of ABS-1230 | Measured from Day 1 to End of Study or Early Termination (up to 2 weeks) | To evaluate the pharmacokinetics of single dose of ABS-1230 |
| Maximum Plasma Concentration [Cmax] After Multiple Doses of ABS-1230 | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To evaluate the pharmacokinetics of multiple doses of ABS-1230 |
| Maximum Plasma Exposure [AUCtau] After Multiple Doses of ABS-1230 | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To evaluate the pharmacokinetics of multiple doses of ABS-1230 |
| Maximum Plasma Concentration [Cmax] After Fed, Fasted and in Combination with Omeprazole Doses of ABS-1230 | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To evaluate the pharmacokinetics of fed, fasted, and in combination with omeprazole doses of ABS-1230 |
| Maximum Plasma Exposure [AUCtau] After Fed, Fasted and in Combination with Omeprazole Doses of ABS-1230 | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To evaluate the pharmacokinetics of fed, fasted, and in combination with omeprazole doses of ABS-1230 |
| Maximum Plasma Concentration [Cmax] of ABS-1230 in Combination with Voriconazole | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To evaluate the pharmacokinetics ABS-1230 in combination with voriconazole |
| Maximum Plasma Exposure [AUCtau] of ABS-1230 in Combination with Voriconazole | Measured from Day 1 to End of Study or Early Termination (up to 4 weeks) | To evaluate the pharmacokinetics ABS-1230 in combination with voriconazole |
Countries
Australia
Contacts
CONTACTActio Biosciences, Inc.
STUDY_DIRECTORMedical Director
Actio Bioscences, Inc.
Outcome results
None listed